Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31389771 | 0.92 | SIGMAR1 (0.38) | HDAC1HDAC6SIGMAR1KCNH2NOTUM | |
| SCHEMBL31389736 | 0.90 | SIGMAR1 (0.43) | HDAC1HDAC6SIGMAR1KCNH2KDM4E | |
| SCHEMBL24958728 | 0.87 | MEN1 (0.37) | MAPT | |
| SCHEMBL24915358 | 0.87 | SIGMAR1 (0.41) | HDAC1HDAC6SIGMAR1 | |
| SCHEMBL24915584 | 0.82 | P2RX7 (0.33) | HDAC1HDAC6SIGMAR1P2RX7 | |
| SCHEMBL28942409 | 0.82 | EPHX2 (0.35) | L3MBTL1KDM4E | |
| SCHEMBL24964682 | 0.82 | HDAC1 (0.36) | HDAC1HDAC6SIGMAR1KCNH2NOTUM | |
| SCHEMBL25238346 | 0.82 | HDAC1 (0.36) | HDAC1HDAC6SIGMAR1KCNH2 | |
| SCHEMBL19945613 | 0.82 | HDAC1 (0.36) | HDAC1HDAC6SIGMAR1KCNH2CCR1 | |
| SCHEMBL17381874 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051313-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-02-13 | — | — | US | disclosed |
| CN-116348109-B | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118434720-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118373808-A | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-113748110-B | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3877387-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| US-10633375-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | Jinagsu Hengrui Medicine Co., Ltd (CN) | 2020-04-28 | — | — | US | disclosed |
| US-20190185464-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3486242-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-3486242-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018041122-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633375-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | F11, F2, F7 | HDAC1 1936/4885HDAC6 2181/4885SIGMAR1 4207/4885 |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, F2, F7 | HDAC1 2425/4885HDAC6 2837/4885SIGMAR1 4330/4885 |
| US-20250051313-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK4, PDK2, PDK3 | HDAC1 117/4885HDAC6 319/4885SIGMAR1 4262/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | HDAC1 1434/4885HDAC6 1395/4885SIGMAR1 1355/4885 |
| US-20190185464-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, F2, F7 | HDAC1 1936/4885HDAC6 2181/4885SIGMAR1 4207/4885 |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | F11, F2, F7 | HDAC1 1936/4885HDAC6 2181/4885SIGMAR1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.